Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy

Transplant Proc. 1997 Feb-Mar;29(1-2):1549. doi: 10.1016/s0041-1345(96)00671-9.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Costs and Cost Analysis
  • Graft Rejection / economics
  • Graft Rejection / therapy*
  • Humans
  • Illinois
  • Immunosuppressive Agents / economics*
  • Immunosuppressive Agents / therapeutic use
  • Length of Stay / economics
  • Muromonab-CD3 / economics*
  • Muromonab-CD3 / therapeutic use
  • Tacrolimus / economics*
  • Tacrolimus / therapeutic use

Substances

  • Immunosuppressive Agents
  • Muromonab-CD3
  • Tacrolimus